Clinical-stage biotechnology company Lineage Cell Therapeutics has appointed George Samuel as general counsel and corporate secretary.
Samuel was most recently director and senior counsel for Lytx, a role in which he managed the commercial legal operations for the international video telematics tech company. Before that, he was vice president, general counsel and corporate secretary for Cardiff Oncology, formerly known as Trovagene, a clinical-stage biotechnology company focused on developing treatments in oncology.
During his time with Cardiff Oncology, Samuel advised on strategic, business development and operational decisions; oversaw capital raising efforts, regulatory compliance and SEC reporting; and managed intellectual property matters, including technology transfer and licensing.
He has also practiced corporate law at firms including DLA Piper and Cooley, where advised clients on a variety of commercial transactions.
‘We are pleased to welcome George to our leadership team and look forward to his contributions as we build Lineage into a leading cell therapy and cell transplant company,’ Lineage CEO Brian Culley says in a statement.
‘George’s diverse experience across legal and other operational areas will be invaluable as we continue to execute on our clinical development plans. In particular, his transactional successes in business development and his intellectual property experience will be key resources as we evaluate partnership opportunities and expand collaborations.’
Â
Ben Maiden
Ben Maiden is the editor-at-large of Governance Intelligence, an IR Media publication, having joined the company in December 2016. He is based in New York. Ben was previously managing editor of Compliance Reporter, covering regulatory and compliance...
